Open Medicine (Sep 2022)

SELENBP1 inhibits progression of colorectal cancer by suppressing epithelial–mesenchymal transition

  • Zhang Xiaotian,
  • Hong Runqi,
  • Bei Lanxin,
  • Hu Zhiqing,
  • Yang Ximin,
  • Song Tao,
  • Chen Liang,
  • Meng He,
  • Niu Gengming,
  • Ke Chongwei

DOI
https://doi.org/10.1515/med-2022-0532
Journal volume & issue
Vol. 17, no. 1
pp. 1390 – 1404

Abstract

Read online

Selenium-binding protein 1 (SELENBP1) is frequently dysregulated in various malignancies including colorectal cancer (CRC); however, its roles in progression of CRCs and the underlying mechanism remain to be elucidated. In this study, we compared the expression of SELENBP1 between CRCs and colorectal normal tissues (NTs), as well as between primary and metastatic CRCs; we determined the association between SELENBP1 expression and CRC patient prognoses; we conducted both in vitro and in vivo experiments to explore the functional roles of SELENBP1 in CRC progression; and we characterized the potential underlying mechanisms associated with SELENBP1 activities. We found that the expression of SELENBP1 was significantly and consistently decreased in CRCs than that in adjacent NTs, while significantly and frequently decreased in metastatic than primary CRCs. High expression of SELENBP1 was an independent predictor of favorable prognoses in CRC patients. Overexpression of SELENBP1 suppressed, while silencing of SELENBP1 promoted cell proliferation, migration and invasion, and in vivo tumorigenesis of CRC. Mechanically, SELENBP1 may suppress CRC progression by inhibiting the epithelial–mesenchymal transition.

Keywords